Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.021
Schlusskurs vom Vortag:
$0.021
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$N/A
Einnahmen:
$13.53M
Nettoeinkommen (Verlust:
$-44.07M
KGV:
0.00
EPS:
-28.2101
Netto-Cashflow:
$-23.86M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-85.40%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
Firmenname
Telesis Bio Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare TBIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.00 | 0 | 13.53M | -44.07M | -23.86M | -28.21 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-03-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-03-18 | Herabstufung | Truist | Buy → Hold |
| 2020-10-05 | Eingeleitet | Goldman | Buy |
| 2020-07-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-06 | Eingeleitet | William Blair | Outperform |
| 2020-06-26 | Eingeleitet | SunTrust | Buy |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-06-18 | Eingeleitet | ROTH Capital | Buy |
| 2018-12-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-07-23 | Eingeleitet | Citigroup | Buy |
| 2018-07-23 | Eingeleitet | Evercore ISI | Outperform |
| 2018-07-23 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Telesis Bio Inc Aktie (TBIO) Neueste Nachrichten
J. Craig Venter launches genomics startup designed to boost diagnostic insights - Fierce Biotech
Statement of Changes in Beneficial Ownership (4) - ADVFN
Current Report Filing (8-k) - ADVFN
Small Company Offering and Sale of Securities Without Registration (d) - ADVFN
DNA Manufacturing Market Size to Hit USD 20.28 Billion by - GlobeNewswire
Enzymatic DNA Synthesis Market | Global Market Analysis Report2035 - Future Market Insights
WhiteFiber Shares Rise in Nasdaq Debut - MarketScreener
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
From California to Cambridge: finance ace strengthens Nuclera board - Business Weekly
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio secures $3 million in promissory notes By Investing.com - Investing.com Nigeria
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio Inc. (TBIO) Quarterly 10-Q Report - qz.com
Technical Analysis of Telesis Bio, Inc. (OTC:TBIO) - TradingView
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView — Track All Markets
Telesis Bio Stock Is Soaring Wednesday: What's Going On? - TradingView — Track All Markets
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Telesis Bio Inc. (NASDAQ: TBIO)Share Price - intelligentinvestor.com.au
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.31% - Investing.com UK
Telesis Bio to delist from Nasdaq by end of September - Investing.com
Telesis Bio reshuffles board, appoints new chairs - Investing.com India
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Yuan Yang completed the acquisition of Eton Bioscience, Inc. from Telesis Bio, Inc. - marketscreener.com
Telesis Bio, Inc. Approves Board Changes - MarketScreener
DNA Synthesis Market Size, Share | Growth Report [2034] - Fortune Business Insights
Automating DNA Synthesis Boosts Drug Discovery: - Mary Ann Liebert, Inc.
Telesis Bio announces reverse stock split By Investing.com - Investing.com Nigeria
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results - Macau Business
About Us - FinancialContent
Pre-market Movers: HSCS, RNA, THAR, BGLC... - RTTNews
Telesis Bio: Q3 Earnings Snapshot - qz.com
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA - FinancialContent
Laser Focus WorldTelesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS - FinancialContent
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. | News | Sidley Austin LLP - Sidley Austin
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor - marketscreener.com
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023 - Koreabizwire
Eyepoint Pharmaceuticals (NASDAQ:EYPT), GeoVax Labs (NASDAQ:GOVX), Telesis Bio (NASDAQ:TBIO), Organovo Holdings (NASDAQ:ONVO), TRACON Pharmaceuticals (NASDAQ:TCON), and Abivax: Six Biotech Companies, Six Strategies - The Wall Street Transcript
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up - SynBioBeta
Synthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego Facility - Forbes
Townhall - FinancialContent
What is the current Price Target and Forecast for TELESIS BIO (TBIO) - Zacks Investment Research
Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Stock Titan
Finanzdaten der Telesis Bio Inc-Aktie (TBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
0.51%
Kapitalisierung:
|
Volumen (24h):